Sign In
Buy LPTX
$0.690
+0 (+0%)
At Close: Jun 23, 2026
Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass.
Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript
01:42pm, Monday, 31'st Mar 2025
Leap Therapeutics (NASDAQ:LPTX ) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi - President and CEO Cyndi Sirard
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
01:29pm, Wednesday, 26'th Mar 2025
Leap Therapeutics, Inc. LPTX presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Exper
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
07:05am, Wednesday, 26'th Mar 2025
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
07:00am, Wednesday, 26'th Mar 2025
Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy S
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
07:00am, Tuesday, 28'th Jan 2025
35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 level
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer
07:01am, Monday, 06'th Jan 2025
Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early trial data in GI cancers. LPTX has a short operational runway with less than a
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 06'th Jan 2025
CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dou
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
07:00am, Tuesday, 26'th Nov 2024
CAMBRIDGE, Mass. , Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do
Leap Therapeutics Reports Third Quarter 2024 Financial Results
07:00am, Wednesday, 13'th Nov 2024
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia
CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that
3 Trending Biotech Penny Stocks
11:41am, Thursday, 22'nd Aug 2024
Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.
Leap Therapeutics Reports Second Quarter 2024 Financial Results
07:00am, Monday, 12'th Aug 2024
CAMBRIDGE, Mass. , Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financ
Leap Therapeutics Reports First Quarter 2024 Financial Results
07:00am, Monday, 13'th May 2024
CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial
Leap Therapeutics Announces $40 Million Private Placement
08:30am, Thursday, 11'th Apr 2024
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and developme
